BioCryst Pharmaceuticals | BCRX - 普通股股本

金融业

USD

USD 557.85M

现金及等价物

USD 154.97M

USD 3.84M

USD 484.68M

USD 208.85M

USD 828.6M

股息收益率

0

USD 98.47M

USD 51.7M

536

EPS每股收益

USD 0.3

股本和储备

USD -454.29M

USD 214.41M

债务利息支出

USD 21.71M

USD -0.13

USD 395.4M

USD 1.79B

USD 78.4M

USD 119.79M

USD 98.47M

普通股股本

USD 255.27M

6.84

USD 248.02M

USD 218.25M

销售和管理费用

USD 63.98M

USD 6.06M

贸易债权人

USD 11.46M

应收帐款人

USD 110.76M

	普通股股本	更改		日
Alnylam Pharmaceuticals	USD 133.73M		290K	2026-06
BioCryst Pharmaceuticals	USD 255.26M		42.2M	2026-06
Chugai Pharma	JPY 1.65B		460K	2026-06
Daiichi Sankyo	JPY 1.82B		30.68M	2026-06
DBV Technologies	USD 235.6M		98.78M	2025-12
Enanta Pharmaceuticals	USD 212K		1000	2023-12
Gilead Sciences	USD 1.24B		1000K	2026-06
GlaxoSmithKline	GBP 4.08B		20.6M	2026-06
Glaxosmithkline	GBP 4.05B		20.6M	2026-03
Incyte	USD 200.98M		1.03M	2026-06
Ionis Pharmaceuticals	USD 165.64M		265K	2026-06
Karyopharm Therapeutics	USD 22.54M		4.23M	2026-03
Neurocrine Biosciences	USD 100.55M		50K	2026-06
Novavax	USD 162.58M		106K	2025-12
PTC Therapeutics	USD 82.88M		1.41M	2026-03
Regeneron Pharmaceuticals	USD 105M		300K	2026-03
Roche Holding	CHF 796.77M		1.15M	2026-06
Sarepta Therapeutics	USD 105.62M		53K	2026-06
Ultragenyx Pharmaceutical	USD 98.3M		1.7M	2026-03
Vertex Pharmaceuticals	USD 253.3M		900K	2026-06